A case report of a 46-year-old male patient with anaplastic astrocytoma, isocitrate dehydrogenase (IDH)1 R132 mutation, IDH2 R172 mutation, and a methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter without 1p36 and 19q13 heterozygosity loss demonstrated the potential of combined TTFields and chemotherapy to reduce the risks for pathological upgrade [63]. This evidence concerns the gene MGMT and anaplastic astrocytoma.